1007882-23-6

• 常用中文名：达卡他韦中间体II
• 常用英文名：HCV-IN-30
• CAS号：1007882-23-6
• 分子式：C₃₆H₄₄N₆O₄
• 分子量：624.772
• 相关类别： 信号通路 抗感染 HCV
• 发布时间：2018-05-18 08:00:00
• 更新时间：2026-07-08 22:16:09
• HCV-IN-30 (compound 48) 是一种丙型肝炎病毒 HCV NS5A 复制复合物抑制剂,抑制 HCV 1a 和 1b 型复制的 IC50 分别为 901 和 102 nM。

名称

• 中文名: 达卡他韦中间体
• 英文名: di-tert-butyl (2S,2'S)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate)
• 中文别名: (2S,2'S)-二叔丁基 2,2'-(4,4'-([1,1'-双苯基]-4,4'-二基)双(1H-咪唑- 4,2-二基))双(吡咯烷-1-甲酯); (2S,2'S)-2,2'-([1,1'-联苯]-4,4'-二基二-1H-咪唑-5,2-二基)二-1-吡咯烷羧酸 1,1'-二叔丁基酯; (2S,2'S)-二叔丁基2,2'-(4,4'-([1,1'-双苯基]-4,4'-二基)双(1H-咪唑- 4,2-二基))双(吡咯烷-1-甲酯); (2S,2'S)-二叔丁基 2,2'-(4,4'-([1,1'-双苯基]-4,4'-二基)双(1H-咪唑- 4,2-二基))双(吡咯烷-1-甲酯)(中间体2); 达卡他韦中间体2; DK-N-2(达卡他韦中间体2); 达卡他韦中间体 DK N-2; 达卡他韦中间体1007-6; 达卡他韦中间体02; BIS(2-甲基-2-丙基)(2S,2'S)-2,2'-[4,4'-联苯二基双(1H-咪唑-4,2-二基)]二(1-吡咯烷羧酸酯)
• 英文别名: Daclatasvir Intermediates Ⅱ; Di-tert-butyl2,2'-([1,1'-biphenyl]-4,4'-diylbis(1H-imidazole-5,2-diyl))(2S,2'S)-bis(pyridineidine-1; 1,1'-Bis(tert-butyl) (2S,2'S)-2,2'-(biphenyl-4,4'-diyldi-1H-imidazol-5,2-diyl)bis[pyrrolidine-1-cboxylate; Bis(2-methyl-2-propanyl) (2S,2'S)-2,2'-[4,4'-biphenyldiylbis(1H-imidazole-4,2-diyl)]di(1-pyrrolidinecboxylate); 2-(5-(4'-(2-((S)-1-(tert-butoxycbonyl)pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-cboxylate; Daclatasvir Intermediate-2; T5NTJ AVOX1&1&1 B- BT5M CNJ ER DR D- ET5M CNJ B- BT5NTJ AVOX1&1&1 &&(2S,2S'- Form; di-tert-butyl (2S,2'S)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecboxylate); Bis(2-methyl-2-propanyl) (2S,2'S)-2,2'-[4,4'-biphenyldiylbis(1H-imidazole-4,2-diyl)]di(1-pyrrolidinecarboxylate); 2-(4-{4'-[2-((2S)-1-tert-butoxycbonyl-pyrrolidin-2-yl)-1H-imidazol-4-yl]-biphenyl-4-yl}-1H-imidazol-2-yl)-(2S)-pyrrolidine-1-cboxylic acid tert-butyl ester; 1-Pyrrolidinecboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diy; Di-tert-butyl2,2'-([1,1'-biphenyl]-4,4'-diylbis(1H-imidazole-5,2-diyl))(2S,2'S)-bis(pyridineidine-1-cboxylate); 1-Pyrrolidinecboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-iMidazole-5,2-diyl)bis-, 1,1'-bis(1,1-diMethylethyl) ester, (2S,2'S); di-tert-butyl (2S,2'S)-2,2'-(4,4'-biphenyldiylbis(lH-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate); Intermediate II of Dacatavir; 1-Pyrrolidinecboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-iMidazole-5,2-diyl)bis-, 1,1'-bis(1,1-diMethylethyl) ester, (2S,2'S)-nyl; (2S,2''S)-Di-tert-butyl 2,2''-(5,5''-([1,1''-biphenyl]-4,4''-diyl)bis(1h-imidazole-5,2-diyl))bis(pyrrolidine-1-cboxylate); (2S,2'S); Daclatasvir Intermediates; Bis(1,1-dimethylethyl) (2,2'-[[1,1'-biphenyl]-4,4'-diylbis(1H-imidazole-5,2-diyl)]bis(1-pyrrolidinecarboxylate); 1-Pyrrolidinecboxylic acid, 2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H; Daclatasvir intermediate 02; HCV-IN-30, 10 mM in DMSO; Daclatasvir Intermediates 4; (2S,2'S)-2,2'-[(1,1'-biphenyl)-4,4'-diyldi-1H-imidazole-5,2-diyl]bis-1-pyrrolidinecboxylic acid ,1,1'-bis(1,1-dimethylethyl) ester; Dacaltasvir Intermediate 02; (2S,2'S)-DI-TERT-BUTYL-2,2'-(4,4'-([1,1'-BIPHENYL]-4,4'-DIYL - )BIS(1H-IMIDAZOLE-4,2-DIYL))BIS(PYRROLIDINE-1-CARBOXYLATE); Daclatasvir intermediate; 1-Pyrrolidinecboxylic acid,2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-imidazole-5,2-diyl)bis; 1,1'-Bis(1,1-dimethylethyl) (2S,2'S)-2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-imidazole-5,2-diyl)bis[1-pyrrolidinecboxylate; Methyl-N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]cbamate; Di-tert-butyl (2S,2'S)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate); di-tert-butyl(2S,2'S)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate); di-tert-butyl2,2'-([1,1'-biphenyl]-4,4'-diylbis(1H-imidazole-5,2-diyl))(2S,2'S)-bis(pyrrolidine-1-cboxylate); (2S,2'S)-2,2'-([1,1'-Biphenyl]-4,4'-diyldi-1H-imidazole-5,2-diyl)bis-1-pyrrolidinecboxylic acid 1,1'-bis(1,1-dimethylethyl) ester; (2S,2'S)-di-tert-butyl 2,2'-(4,4'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-iMidazole-4,2-diyl))bis(pyrrolidine-1-cboxylate); EOS-61352

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 890.2±65.0 °C at 760 mmHg
• 分子式: C₃₆H₄₄N₆O₄
• 分子量: 624.772
• 闪点: 492.2±34.3 °C
• 精确质量: 624.342407
• PSA: 116.44000
• LogP: 5.69
• 蒸汽压: 0.0±0.3 mmHg at 25°C
• 折射率: 1.600
• 储存条件: 2-8°C，干燥密封

生物活性

• 描述: HCV-IN-30 (compound 48) 是一种丙型肝炎病毒 HCV NS5A 复制复合物抑制剂,抑制 HCV 1a 和 1b 型复制的 IC50 分别为 901 和 102 nM。
• 相关类别:
  信号通路 >> 抗感染 >> HCV
  研究领域 >> 感染
• 参考文献:

  [1]. Belema M, et al. Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons. J Med Chem. 2014 Mar 13;57(5):1995-2012.